Greenwood Capital Associates LLC Sells 10,733 Shares of Apyx Medical Co. (NASDAQ:APYX)

Greenwood Capital Associates LLC lessened its stake in Apyx Medical Co. (NASDAQ:APYX) by 4.0% in the third quarter, HoldingsChannel reports. The firm owned 257,820 shares of the company’s stock after selling 10,733 shares during the period. Greenwood Capital Associates LLC’s holdings in Apyx Medical were worth $320,000 as of its most recent filing with the Securities and Exchange Commission.

Other large investors have also added to or reduced their stakes in the company. Commonwealth Equity Services LLC purchased a new position in shares of Apyx Medical during the 1st quarter worth $676,000. Kingsview Wealth Management LLC boosted its stake in shares of Apyx Medical by 156.7% during the 1st quarter. Kingsview Wealth Management LLC now owns 31,028 shares of the company’s stock worth $42,000 after acquiring an additional 18,943 shares during the last quarter. Perkins Capital Management Inc. boosted its stake in shares of Apyx Medical by 7.0% during the 1st quarter. Perkins Capital Management Inc. now owns 228,500 shares of the company’s stock worth $311,000 after acquiring an additional 15,000 shares during the last quarter. Rathbones Group PLC boosted its stake in shares of Apyx Medical by 148.0% during the 2nd quarter. Rathbones Group PLC now owns 251,334 shares of the company’s stock worth $337,000 after acquiring an additional 150,000 shares during the last quarter. Finally, RPg Family Wealth Advisory LLC purchased a new position in shares of Apyx Medical during the 2nd quarter worth $101,000. Institutional investors own 55.33% of the company’s stock.

Apyx Medical Stock Up 0.9 %

APYX opened at $1.17 on Wednesday. The company has a debt-to-equity ratio of 2.26, a quick ratio of 4.45 and a current ratio of 5.33. Apyx Medical Co. has a fifty-two week low of $0.97 and a fifty-two week high of $3.26. The firm’s fifty day moving average is $1.21 and its 200 day moving average is $1.33. The stock has a market cap of $40.53 million, a price-to-earnings ratio of -1.43 and a beta of 1.21.

Apyx Medical (NASDAQ:APYX) last announced its quarterly earnings results on Thursday, August 8th. The company reported ($0.19) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.18) by ($0.01). The company had revenue of $12.15 million during the quarter, compared to the consensus estimate of $12.67 million. Apyx Medical had a negative net margin of 57.86% and a negative return on equity of 105.45%. During the same quarter in the prior year, the firm posted ($0.11) earnings per share. On average, sell-side analysts forecast that Apyx Medical Co. will post -0.7 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

Several research analysts have recently weighed in on APYX shares. Craig Hallum upgraded shares of Apyx Medical to a “strong-buy” rating in a research note on Thursday, October 24th. BTIG Research assumed coverage on shares of Apyx Medical in a research note on Thursday, October 17th. They set a “neutral” rating on the stock. Finally, JMP Securities restated a “market perform” rating on shares of Apyx Medical in a research note on Monday, September 16th.

Apyx Medical Profile

Apyx Medical Corporation, an energy technology company, engages in the design, development, and manufacture of medical devices in the United States and internationally. The company operates through two segments: Advanced Energy and Original Equipment Manufacturing (OEM). It offers Helium Plasma Generator for delivery of RF energy and helium plasma to cut, coagulate, and ablate soft tissue during open and minimally invasive surgical procedures.